Senior Investigator and Head, Molecular Cancer Section 

Ramaprasad Srinivasan, M.D., Ph.D. is a Senior Investigator in the NCI intramural program and serves as the Head of the Molecular Cancer Section, Urologic Oncology Branch, Center for Cancer Research. He is an internationally renowned physician-scientist in the field of kidney cancer. Dr. Srinivasan leads the efforts to develop novel treatment strategies for patients with kidney cancer within the NCI. His work is focused on developing and evaluating individualized, mechanism-based proof-of-concept studies based on the recognition that there are inherent genetic and molecular differences between various subtypes of kidney cancer  He has pioneered the evaluation of systemic treatment strategies in patients with von Hippel Lindau disease (VHL), and co-led an international study that led to the FDA approval of the HIF2 a inhibitor, belzutifan, heralding a paradigm shift in the management of VHL. His work has also led to the development of a new standard of care in patients with metastatic kidney cancer associated with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). He is currently investigating a variety of newer 'targeted' agents as well as novel immunotherapy approaches, in clear cell and papillary kidney cancer, as well as a number of hereditary kidney cancer syndromes.

Dr. Srinivasan obtained his medical degree from the Bangalore Medical College in India and subsequently completed his Ph.D. in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to the NCI in 1999 after completing his internal medicine residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in medical oncology/hematology.

Dr. Srinivasan serves on numerous NIH and extramural committees and on the editorial board of several journals. He is an investigator on numerous clinical trials and has authored over a hundred scientific papers and book chapters. He is the recipient of two NCI Director’s awards, recognizing his contributions to the development of new treatments for patients with kidney cancer and promoting diversity, equity and inclusion in clinical trials.